American journal of clinical dermatology
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).
Christopher G Bunick, Nina Magnolo, Angela Moore, Masatoshi Abe, Xinghua Gao, Charles Lynde, Nadia Ibrahim, Gweneth Levy, Brian M Calimlim, Xiaoqiang Wu, Yolanda Armendariz, Ayman Grada, Kilian Eyerich
Published: 202610.1007/s40257-025-01003-0
Abstract
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itch and eczematous skin lesions. Upadacitinib, a selective oral Janus kinase inhibitor, and dupilumab, a monoclonal antibody, are both approved treatm…
Preview only. Read the full abstract at the source